Company Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:30:00 13/05/2024 BST			5-day change	1st Jan Change
1.44 ^USD	-0.69%		-12.73%	-58.62%

05-01	Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	CI
04-24	Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	CI

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

Managers	Title	Age	Since
Thomas Meyer CEO	Chief Executive Officer	56	31/03/03
Marcel Gremaud DFI	Director of Finance/CFO	66	31/10/21
Covadonga Pañeda COO	Chief Operating Officer	51	-
Samuel Wickline CTO	Chief Tech/Sci/R&D Officer	71	31/05/21

Members of the board	Title	Age	Since
Alain Munoz BRD	Director/Board Member	75	28/02/18
Mats Blom BRD	Director/Board Member	59	31/03/17
Thomas Meyer CEO	Chief Executive Officer	56	31/03/03
Margrit Schwarz BRD	Director/Board Member	60	20/07/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,240,245	2,220,245 ( 99.11 %)	0	99.11 %

Name	Equities	%	Valuation
Thomas Meyer 1.268 %	20,000	1.268 %	41 400 $
UBS Securities LLC 0.4319 %	6,814	0.4319 %	14 105 $
Tower Research Capital LLC 0.0539 %	851	0.0539 %	1 762 $
Group One Trading LP 0.000887 %	14	0.000887 %	29 $
Alain Munoz 0.000000 %	0	0.000000 %	- $
Mats Blom 0.000000 %	0	0.000000 %	- $
Margrit Schwarz 0.000000 %	0	0.000000 %	- $
Marcel Gremaud 0.000000 %	0	0.000000 %	- $
Decalia Asset Management SIM SpA 0.000000 %	0	0.000000 %	- $

Altamira Therapeutics Ltd.

Clarendon House 2 Church Street

HM 11, Hamilton

+441 295 5950

http://www.altamiratherapeutics.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs